CRADA Number NFE-19-07859 with Purist, Inc. (CRADA Final Report)
Cooperative Research and Development Agreement (CRADA) NFE-19-07859 between Oak Ridge National Laboratory (ORNL) and Purist Inc. (Purist) focused on developing a technology for production of high purity radioisotopes using small-scale underutilized research nuclear reactors. Purist is developing a novel production mechanism that will produce, and efficiently isolate radioisotopes with high specific activity at small-scale research reactors. The goal of this technology is to enable underutilized smaller scale reactors, typically not capable of producing medical grade radioisotopes, to be utilized as a production supply source. Such radioisotope production facilities will complement production efforts of the few larger production facilities to reduce and prevent risk in the medical isotope supply chain. The work done under this CRADA explored target development, to maximize isotope production and separation using Purist’s technology to ultimately obtain a radioisotope product with high specific activity for use in medical applications. Furthermore, under this CRADA post production, capture, concentration and encapsulation of the radioisotope product was studied by developing post irradiation midi to microscale processes to capture, store and release the separated radioisotopes from large volumes of the capture matrix after production, via automated High-Pressure Ion Chromatography (HPIC) and microfluidic purification/separation systems. This will enable concentration of the radioisotope product obtained into small volumes, which will aid in packaging and transporting the final radioisotope product to users.